TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition

Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of abnormal clonal plasma cells in the bone marrow. Introduction of the proteasome-inhibitor bortezomib has improved MM prognosis and survival; however hypoxia-induced or acquired bortezomib resistance remains a clinical p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Cycle
Hlavní autoři: Raninga, Prahlad V., Di Trapani, Giovanna, Vuckovic, Slavica, Tonissen, Kathryn F.
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis 2016
Témata:
Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5056617/
https://ncbi.nlm.nih.gov/pubmed/26743692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2015.1136038
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky